Chronic Lymphocytic Leukemia

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.

“The regimen of obinutuzumab, ibrutinib, and venetoclax met its primary goal of achieving deep remissions with a fixed-duration combination of targeted agents.”

In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the current treatment landscape for patients with chronic lymphocytic leukemia and some of the latest research regarding the BTK inhibitors.

The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic leukemia. However, age and the existence of comorbidities may not impact death from COVID-19, according to results from a retrospective international study.

Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.

Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.

During a virtual Case Based Peer Perspectives event, Steven Coutre, MD, reviewed a case of a 53-year-old woman who first presented with elevated white blood cell count. The patient was later diagnosed with chronic lymphocytic leukemia.

During a virtual Case Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed a case of a 71-year-old woman diagnosed with chronic lymphocytic leukemia.

The triplet combination of obinutuzumab plus ibrutinib with venetoclax demonstrated encouraging response rates in patients with treatment-naïve chronic lymphocytic leukemia.

Marc Hoffman, MD, reviewed a case of a 61-year-old man with chronic lymphocytic leukemia, during a virtual Case Based Peer Perspectives event.

Alexey Danilov, MD, PhD, discussed the case of 71-year-old woman with relapsed/refractory chronic lymphocytic leukemia during a virtual Case Based Peer Perspectives event.

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Matthew S. Davids, MD, discusses the long-term follow-up of a phase 1/1b trial for patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma receiving ibrutinib and umbralisib.

In the phase 3 DUO clinical trial, treatment with duvelisib improved health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia compared with ofatumumab.

"We are excited about cirmtuzumab’s potential for the treatment of patients with ROR1-expressing cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, HER2-negative breast cancer, and other solid tumors, and look forward to further advancing its development to benefit patients with significant unmet medical needs."

In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.

All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.

During a debate made available as part of the 2020 National Comprehensive Cancer Network Virtual Annual Conference, Deborah Stephens, DO, and Mazyar Shadman, MD, MPH, discussed the most optimal frontline therapy for chronic lymphocytic leukemia.

Hun Ju Lee, MD, discusses the clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib in a phase 1b/2 study of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.